Page 209 - Read Online

Alonso-Peña et al. Cancer Drug Resist 2019;2:680-709 I http://dx.doi.org/10.20517/cdr.2019.006 Page 705

75. Chen YL, Chen PM, Lin PY, Hsiau YT, Chu PY. ABCG2 Overexpression Confers Poor Outcomes in Hepatocellular Carcinoma of
Elderly Patients. Anticancer Res 2016;36:2983-8.
76. Marin JJG, Lozano E, Briz O, Al-Abdulla R, Serrano MA, Macias RIR. Molecular Bases of Chemoresistance in Cholangiocarcinoma.
Curr Drug Targets 2017;18:889-900.
77. Prasad B, Lai Y, Lin Y, Unadkat JD. Interindividual variability in the hepatic expression of the human breast cancer resistance protein
(BCRP/ABCG2): effect of age, sex, and genotype. J Pharm Sci 2013;102:787-93.
78. Ahmed S, Zhou Z, Zhou J, Chen SQ. Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision
Medicine. Genomics Proteomics Bioinformatics 2016;14:298-313.
79. Zhou J, Wen Q, Li SF, Zhang YF, Gao N, et al. Significant change of cytochrome P450s activities in patients with hepatocellular
carcinoma. Oncotarget 2016;7:50612-23.
80. Rochat B. Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and
imatinib metabolism. Clin Pharmacokinet 2005;44:349-66.
81. Zhong JH, Xiang BD, Ma L, You XM, Li LQ, et al. Meta-analysis of microsomal epoxide hydrolase gene polymorphism and risk of
hepatocellular carcinoma. PLoS One 2013;8:e57064.
82. Korobkova EA. Effect of natural polyphenols on CYP metabolism: implications for diseases. Chem Res Toxicol 2015;28:1359-90.
83. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact
of genetic variation. Pharmacol Ther 2013;138:103-41.
84. Miyoshi Y, Taguchi T, Kim SJ, Tamaki Y, Noguchi S. Prediction of response to docetaxel by immunohistochemical analysis of CYP3A4
expression in human breast cancers. Breast Cancer 2005;12:11-5.
85. Yan T, Lu L, Xie C, Chen J, Peng X, et al. Severely impaired and dysregulated cytochrome p450 expression and activities in hepatocellular
carcinoma: implications for personalized treatment in patients. Mol Cancer Ther 2015;14:2874-86.
86. Fushiya N, Takagi I, Nishino H, Akizuki S, Ohnishi A. Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic
efficacy in patients with hepatocellular carcinoma. Anticancer Drugs 2013;24:617-22.
87. Sugiyama E, Kaniwa N, Kim SR, Kikura-Hanajiri R, Hasegawa R, et al. Pharmacokinetics of gemcitabine in Japanese cancer patients:
the impact of a cytidine deaminase polymorphism. J Clin Oncol 2007;25:32-42.
88. Fujimura T, Takahashi S, Urano T, Kumagai J, Murata T, et al. Expression of cytochrome P450 3A4 and its clinical significance in human
prostate cancer. Urology 2009;74:391-7.
89. Oguro A, Sakamoto K, Suzuki S, Imaoka S. Contribution of hydrolase and phosphatase domains in soluble epoxide hydrolase to
vascular endothelial growth factor expression and cell growth. Biol Pharm Bull 2009;32:1962-7.
90. Omiecinski CJ, Hassett C, Hosagrahara V. Epoxide hydrolase--polymorphism and role in toxicology. Toxicol Lett 2000;112-113:365-70.
91. Marin JJ, Briz O, Monte MJ, Blazquez AG, Macias RI. Genetic variants in genes involved in mechanisms of chemoresistance to
anticancer drugs. Curr Cancer Drug Targets 2012;12:402-38.
92. Hassett C, Aicher L, Sidhu JS, Omiecinski CJ. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression
in vitro of amino acid variants. Hum Mol Genet 1994;3:421-8.
93. Jiang W, Lu Z, He Y, Diasio RB. Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-
based chemotherapy. Clin Cancer Res 1997;3:395-9.
94. Walko CM, McLeod HL. Will we ever be ready for blood level-guided therapy? J Clin Oncol 2008;26:2078-9.
95. Etienne-Grimaldi MC, Boyer JC, Beroud C, Mbatchi L, van Kuilenburg A, et al. New advances in DPYD genotype and risk of severe
toxicity under capecitabine. PLoS One 2017;12:e0175998.
96. Hiratsuka M, Yamashita H, Akai F, Hosono H, Hishinuma E, et al. Genetic polymorphisms of dihydropyrimidinase in a Japanese patient
with capecitabine-induced toxicity. PLoS One 2015;10:e0124818.
97. Lin L, Sun J, Tan Y, Li Z, Kong F, et al. Prognostic implication of NQO1 overexpression in hepatocellular carcinoma. Hum Pathol
2017;69:31-7.
98. Buranrat B, Prawan A, Kukongviriyapan U, Kongpetch S, Kukongviriyapan V. Dicoumarol enhances gemcitabine-induced cytotoxicity
in high NQO1-expressing cholangiocarcinoma cells. World J Gastroenterol 2010;16:2362-70.
99. Zhou JY, Shi R, Yu HL, Zheng WL, Ma WL. Association of NQO1 Pro187Ser polymorphism with the risks for colorectal cancer and
colorectal adenoma: a meta-analysis. Int J Colorectal Dis 2012;27:1123-4.
100. Kolesar JM, Dahlberg SE, Marsh S, McLeod HL, Johnson DH, et al. The NQO1*2/*2 polymorphism is associated with poor overall
survival in patients following resection of stages II and IIIa non-small cell lung cancer. Oncol Rep 2011;25:1765-72.
101. Mameri H, Bieche I, Meseure D, Marangoni E, Buhagiar-Labarchede G, et al. Cytidine deaminase deficiency reveals new therapeutic
opportunities against cancer. Clin Cancer Res 2017;23:2116-26.
102. Carpi FM, Vincenzetti S, Ubaldi J, Pucciarelli S, Polzonetti V, et al. CDA gene polymorphisms and enzyme activity: genotype-
phenotype relationship in an Italian-Caucasian population. Pharmacogenomics 2013;14:769-81.
103. Tibaldi C, Giovannetti E, Tiseo M, Leon LG, D'Incecco A, et al. Correlation of cytidine deaminase polymorphisms and activity with
clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients. Ann Oncol 2012;23:670-7.
104. Coulibaly ST, Rossolillo P, Winter F, Kretzschmar FK, Braye M, et al. Potent Sensitisation of Cancer Cells to Anticancer Drugs by a
Quadruple Mutant of the Human Deoxycytidine Kinase. PLoS One 2015;10:e0140741.
105. Akhdar H, El Shamieh S, Musso O, Desert R, Joumaa W, et al. The rs3957357C>T SNP in GSTA1 Is Associated with a Higher Risk of
Occurrence of Hepatocellular Carcinoma in European Individuals. PLoS One 2016;11:e0167543.
106. Gamage N, Barnett A, Hempel N, Duggleby RG, Windmill KF, et al. Human sulfotransferases and their role in chemical metabolism.